

# The Medical Letter<sup>®</sup>

## on Drugs and Therapeutics

Volume 65

May 29, 2023

ISSUE No.  
**1677**

### IN THIS ISSUE

Live Fecal Microbiota Oral Capsules (Vowst) for Prevention of CDI Recurrence .....p 81

## Important Copyright Message

### FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying, or any distribution of this material without permission to a nonsubscriber is prohibited.

Sharing a password with a nonsubscriber or otherwise making the contents of this site available to third parties is prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)  
or call customer service at: 800-211-2769

# The Medical Letter®

## on Drugs and Therapeutics

Volume 65 (Issue 1677)

May 29, 2023

[Take CME Exams](#)

### ▶ Live Fecal Microbiota Oral Capsules (Vowst) for Prevention of CDI Recurrence

The FDA has approved Vowst (Seres Therapeutics/Nestle HealthScience), an oral capsule containing live fecal microbiota spores, for prevention of additional recurrences of *Clostridioides difficile* infection (CDI) in adults. Vowst is the first orally administered microbiota-based treatment to be approved for this indication. A rectally-administered live fecal microbiota-based suspension (*Rebyota*) was approved in 2022 for the same indication.<sup>1</sup> Neither product is approved for acute treatment of CDI.

#### Pronunciation and Abbreviation Key

Vowst: vowst

CDI = *Clostridioides difficile* infection

**INITIAL EPISODES OF CDI** – All adults with an initial episode of nonfulminant CDI should receive 10 days of oral treatment with fidaxomicin (*Dificid*) or standard-dose vancomycin. Use of fidaxomicin is preferred; compared to vancomycin, it has a narrower spectrum of activity, which limits its effect on the gut microbiome, and it is associated with higher rates of sustained response and fewer recurrences.<sup>2,3</sup>

**RECURRENT CDI** – Most CDI recurrences develop within 60 days after stopping antibacterial treatment; the risk is greatest in the first 2 weeks. The recurrence rate after treatment of an initial episode is typically 20-25%. Patients who have one recurrent episode are at increased risk of additional recurrences; the risk of having multiple recurrences has increased in recent years.<sup>4</sup>

**PREVENTION OF RECURRENCES** – Addition of a single IV dose of the anti-*C. difficile* toxin B antibody **bezlotoxumab** (*Zinplava*) to antibacterial therapy is recommended to prevent further recurrences in adults who have a recurrence of CDI within 6 months of a previous episode. Use of bezlotoxumab can be considered following antibacterial treatment

#### Key Points: Vowst

- ▶ **Description:** Oral capsule containing live fecal microbiota spores manufactured from human donor fecal matter.
- ▶ **Indication:** Prevention of additional recurrences of *Clostridioides difficile* infection (CDI) in adults.
- ▶ **Efficacy:** In one small trial, the rate of CDI recurrence up to 8 weeks after treatment was lower with Vowst than with placebo (12% vs 40%) in patients with  $\geq 3$  recurrences within 12 months.
- ▶ **Adverse Effects:** Flatulence, abdominal distension, abdominal pain, fatigue, constipation, chills, and diarrhea can occur.
- ▶ **Dosage:** 4 capsules once daily for 3 days started 2-4 days after the last dose of antibiotics for treatment of CDI.
- ▶ **Cost:** A 3-day course of treatment costs \$17,500.
- ▶ **Conclusion:** Vowst reduced the risk of recurrent CDI compared to placebo. Its long-term efficacy remains to be established.

of a first episode of CDI in patients who have risk factors for disease recurrence (e.g., age  $\geq 65$  years, severe CDI, immunosuppression).<sup>5</sup> In two trials in patients receiving antibacterial treatment for primary or recurrent CDI, the recurrence rate with addition of bezlotoxumab was significantly lower than that with addition of placebo (16-17% vs 26-28%).<sup>6</sup> Bezlotoxumab may exacerbate heart failure.

A single dose of **Rebyota** (live fecal microbiota rectal suspension) was modestly more effective than placebo in preventing a recurrence of CDI within 8 weeks after treatment of recurrent CDI (estimated treatment success rate of 70.6% vs 57.5%).<sup>1</sup>

**Fecal microbiota transplantation (FMT)**, a process (not FDA-approved) in which donor feces is administered to the recipient via colonoscopy, upper endoscopy, nasoenteric tube, sigmoidoscopy, an enema, or an oral capsule, has been used for patients with multiple recurrences of CDI.<sup>7,8</sup>

**CLINICAL STUDIES** – FDA approval of Vowst was based on the results of a trial (ECOSPOR III) in 182 adults with recurrent CDI ( $\geq 3$  recurrences within 12 months) who received 10-21 consecutive days of standard antibacterial therapy (vancomycin or fidaxomicin) with improvement in CDI symptoms. Patients were randomized to receive Vowst or placebo for 3 days. Up

Table 1. Some Drugs for Prevention of CDI Recurrence

	<i>Zinplava</i>	<i>Rebyota</i>	<i>Vowst</i>
<b>Generic Name</b>	Bezlotoxumab	Fecal microbiota, live-jslm	Fecal microbiota spores, live-brpk
<b>Formulation</b>	1000 mg/40 mL single-dose vial	Suspension for rectal administration; contains 1x10 <sup>9</sup> to 5x10 <sup>10</sup> CFU/mL of fecal microbes	Capsule; each capsule contains 1x10 <sup>6</sup> to 3x10 <sup>7</sup> firmicutes spore CFU
<b>Administration</b>	IV infusion over 60 minutes	Rectally by a healthcare provider	Orally by patient
<b>Dosage</b>	Single 10 mg/kg dose	Single 150-mL dose	4 capsules once daily x 3 days
<b>Cost<sup>1</sup></b>	\$3,800	\$9000	\$17,500

CFU = colony forming units

1. Approximate WAC for one treatment course (one dose of *Zinplava* for a 70-kg patient, one dose of *Rebyota*, and 12 capsules of *Vowst*). WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. May 5, 2023. Reprinted with permission by First Databank, Inc. All rights reserved. ©2023. www.fdbhealth.com/policies/drug-pricing-policy.

to 8 weeks after treatment, the rate of CDI recurrence was lower with *Vowst* than with placebo (12% vs 40%; RR 0.32; number needed to treat [NNT] 3.6).<sup>9</sup> The rate of recurrence at 24 weeks, a secondary endpoint, was 21.3% with *Vowst* and 47.3% with placebo.<sup>10</sup>

No trials directly comparing *Vowst* with bezlotoxumab, *Rebyota*, or FMT for prevention of CDI recurrence are available.

**ADVERSE EFFECTS** — The most common adverse effects of *Vowst* in ECOSPOR III were flatulence, abdominal distension, abdominal pain, fatigue, constipation, chills, and diarrhea; most were mild to moderate in severity. *Vowst* is manufactured from human donor fecal matter that has been tested for a panel of transmissible pathogens, but not for food allergens; the label states that *Vowst* may transmit infectious agents to the recipient.

**DRUG INTERACTIONS** — *Vowst* contains live bacterial spores; concurrent administration of antibacterial drugs is not recommended.

**PREGNANCY AND LACTATION** — No adequate human or animal data on the use of *Vowst* during pregnancy are available.

**DOSAGE AND ADMINISTRATION** — *Vowst* should be started 2-4 days after completing antibacterial treatment for recurrent CDI and at least 8 hours (preferably 24 hours) after drinking 10 ounces of magnesium citrate (to prevent inactivation of bacterial spores in *Vowst* by residual fidaxomicin or vancomycin in the GI tract). The recommended dosage is 4 capsules taken once daily before the first meal of the day for 3 consecutive days. The capsules should be swallowed whole.

**CONCLUSION** — In one small trial, a 3-day course of oral live fecal microbiota spores (*Vowst*) was more effective than placebo in preventing a recurrence of *Clostridioides difficile* infection (CDI) within 8 weeks of treatment in patients who had at least 3 recurrences within 12 months. Its long-term efficacy remains to be established. No head-to-head trials comparing *Vowst* with the anti-*C. difficile* toxin B antibody bezlotoxumab (*Zinplava*), a rectally-administered, live fecal microbiota suspension (*Rebyota*), or fecal microbiota transplant (FMT) are available. ■

1. Live fecal microbiota (*Rebyota*) for prevention of CDI recurrence. *Med Lett Drugs Ther* 2023; 65:35.
2. Treatment of *Clostridioides difficile* infection. *Med Lett Drugs Ther* 2021; 63:137.
3. Fidaxomicin (*Dificid*) for *Clostridium difficile* infection. *Med Lett Drugs Ther* 2011; 53:73.
4. GK Ma et al. Increasing incidence of multiply recurrent *Clostridium difficile* infection in the United States: a cohort study. *Ann Intern Med* 2017; 167:152.
5. S Johnson et al. Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on the management of *Clostridioides difficile* infection in adults. *Clin Infect Dis* 2021; 73:e1029.
6. MH Wilcox et al. Bezlotoxumab for prevention of recurrent *Clostridium difficile* infection. *N Engl J Med* 2017; 376:305.
7. CR Kelly et al. ACG clinical guidelines: prevention, diagnosis, and treatment of *Clostridioides difficile* infections. *Am J Gastroenterol* 2021; 116:1124.
8. NZ Minkoff et al. Fecal microbiota transplantation for the treatment of recurrent *Clostridioides difficile* (*Clostridium difficile*). *Cochrane Database Syst Rev* 2023; 4:CD013871.
9. P Feuerstadt et al. SER-109, an oral microbiome therapy for recurrent *Clostridioides difficile* infection. *N Engl J Med* 2022; 386:220.
10. SH Cohen et al. Extended follow-up of microbiome therapeutic SER-109 through 24 weeks for recurrent *Clostridioides difficile* infection in a randomized clinical trial. *JAMA* 2022; 328:2062.

**PRESIDENT:** Mark Abramowicz, M.D.; **VICE PRESIDENT, EDITOR IN CHIEF:** Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

**CONTRIBUTING EDITORS:** Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

**MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS:** Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

**FULFILLMENT AND SYSTEMS MANAGER:** Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli

**EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS:** Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

**Copyright and Disclaimer:** The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

#### Subscription Services

#### Address:

The Medical Letter, Inc.  
145 Huguenot St. Ste. 312  
New Rochelle, NY 10801-7537  
www.medicalletter.org

#### Customer Service:

Call: 800-211-2769 or 914-235-0500  
Fax: 914-632-1733  
E-mail: [custserv@medicalletter.org](mailto:custserv@medicalletter.org)

#### Permissions:

To reproduce any portion of this issue,  
please e-mail your request to:  
[permissions@medicalletter.org](mailto:permissions@medicalletter.org)

#### Subscriptions (US):

1 year - \$159; 2 years - \$298;  
3 years - \$398. \$65 per year  
for students, interns, residents,  
and fellows in the US and Canada.  
Reprints - \$45 per issue or article

#### Site License Inquiries:

E-mail: [SubQuote@medicalletter.org](mailto:SubQuote@medicalletter.org)  
Call: 800-211-2769  
Special rates available for bulk  
subscriptions.

Get Connected:    

Copyright 2023. ISSN 1523-2859

The  
Medical  
Letter